A Surprising Beneficiary of New Alzheimer’s Drugs: GE HealthCare

Biogen, Eli Lilly drugs to expand imaging market for companies in diagnostics sector.

Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs

The biotech company cited the launch of Alzheimer’s drug Lekembi as part of its new focus…

Big Pharma Bets Big on China

China remains attractive to global pharmaceutical companies, even as many multinationals are turning their attention elsewhere.

Surge in Heart Procedures Helps Drive Johnson & Johnson Revenue

The pharmaceutical company’s net income rose 6.9% to $5.14 billion, or $1.96 per share.

WSJ News Exclusive | Elliott Takes Big Stake in Drugmaker Catalent

The activist is demanding changes in the contract drug manufacturers board.

FDA Approves First Over-the-Counter Birth-Control Pill

The Food and Drug Administration approved the first over-the-counter birth-control pill, significantly increasing access to contraception…

Investor Group Takes Aim at Antibiotics, Demanding Changes From Fast-Food Companies

Concern over the rise of drug-resistant superbugs is spreading beyond hospital wards and health clinics to…

Obesity Drugs Won’t Starve These Other Potential Blockbusters

Shares of developers of fatty liver disease treatments were in decline until Eli Lilly published results…

FDA Approves Leqembi, Extending Alzheimer’s Treatment to More Patients

The agency’s full approval may result in people enrolled in Medicare receiving anti-amyloid treatment.

WSJ News Exclusive | Tyson Foods to Drop ‘No Antibiotics Ever’ Label on Some Chicken Products

The move would cover drugs that are not critical to human health and would apply to…